文献速递泌尿男性生殖肿瘤

多西他赛化疗联合雄激素抑制与放疗治疗局限性高危前列腺癌:随机III期NRG Oncology RTOG 0521试验

Effect of Chemotherapy With Docetaxel With Androgen Suppression and Radiotherapy for Localized High-Risk Prostate Cancer: The Randomized Phase III NRG Oncology RTOG 0521 Trial.
PubMed 文献 · J Clin Oncol · 2019-03-12

多中心随机III期NRG Oncology RTOG 0521试验纳入612例高危非转移性前列腺癌患者,随机接受长期雄激素抑制(AS)联合放疗(RT)±辅助多西他赛化疗(CT)。中位随访5.7年,4年总生存率AS+RT组89% vs AS+RT+CT组93%(HR 0.69;90%CI 0.49-0.97;单侧P=.034),6年无病生存率和远处转移率亦改善;试验提示多西他赛CT可作为与部分高危前列腺癌患者讨论的选项。

要点

  • 4年总生存率AS+RT组89% vs AS+RT+CT组93%(HR 0.69;90%CI 0.49-0.97;单侧P=.034)。
  • 6年远处转移率AS+RT组14% vs AS+RT+CT组9.1%(HR 0.60;95%CI 0.37-0.99;双侧P=.044)。
  • 6年无病生存率AS+RT组55% vs AS+RT+CT组65%(HR 0.76;95%CI 0.58-0.99;双侧P=.043)。

核心结论

  • 对于高危非转移性前列腺癌患者,多西他赛化疗使4年总生存率从89%提高至93%,并改善无病生存率和降低远处转移率。
  • 试验提示多西他赛化疗可作为与部分高危前列腺癌患者讨论的选项。

研究设计与样本

  • 多中心随机III期NRG Oncology RTOG 0521研究,2005年至2009年入组高危非转移性前列腺癌患者。
  • 患者随机接受标准长期雄激素抑制(AS)联合放疗(RT)±辅助多西他赛化疗(CT)。
  • 共入组612例患者,563例可评估;中位前列腺特异性抗原15.1 ng/mL;53%为Gleason评分9至10分;27%为cT3至cT4期;中位随访5.7年。

主要发现

  • 4年总生存率AS+RT组89%(95%CI 84%-92%)vs AS+RT+CT组93%(95%CI 90%-96%)(HR 0.69;90%CI 0.49-0.97;单侧P=.034)。
  • AS+RT组死亡59例,AS+RT+CT组死亡43例;因前列腺癌死亡分别为23例 vs 16例。
  • 6年远处转移率AS+RT组14% vs AS+RT+CT组9.1%(HR 0.60;95%CI 0.37-0.99;双侧P=.044)。
  • 6年无病生存率AS+RT组55% vs AS+RT+CT组65%(HR 0.76;95%CI 0.58-0.99;双侧P=.043)。
  • 两组治疗耐受性均良好。

临床怎么用

  • 作者认为,多西他赛化疗可作为与部分高危前列腺癌患者讨论的选项。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Radiotherapy (RT) plus long-term androgen suppression (AS) are a standard treatment option for patients with high-risk localized prostate cancer. We hypothesized that docetaxel chemotherapy (CT) could improve overall survival (OS) and clinical outcomes among patients with high-risk prostate cancer. PATIENTS AND METHODS: The multicenter randomized NRG Oncology RTOG 0521 study enrolled patients with high-risk nonmetastatic disease between 2005 and 2009. Patients were randomly assigned to receive standard long-term AS plus RT with or without adjuvant CT. RESULTS: A total of 612 patients were enrolled; 563 were evaluable. Median prostate-specific antigen was 15.1 ng/mL; 53% had a Gleason score 9 to 10 cancer; 27% had cT3 to cT4 disease. Median follow-up was 5.7 years. Treatment was well tolerated in both arms. Four-year OS rate was 89% (95% CI, 84% to 92%) for AS + RT and 93% (95% CI, 90% to 96%) for AS + RT + CT (hazard ratio [HR], 0.69; 90% CI, 0.49 to 0.97; one-sided P = .034). There were 59 deaths in the AS + RT arm and 43 in the AS + RT + CT arm, with fewer deaths resulting from prostate cancer in the AS + RT + CT arm versus AS + RT (23 v 16 deaths, respectively). Six-year rate of distant metastasis was 14% for AS + RT and 9.1% for AS + RT + CT, (HR, 0.60; 95% CI, 0.37 to 0.99; two-sided P = .044). Six-year disease-free survival rate was 55% for AS + RT and 65% for AS + RT + CT (HR, 0.76; 95% CI, 0.58 to 0.99; two-sided P = .043). CONCLUSION: For patients with high-risk nonmetastatic prostate cancer, CT with docetaxel improved OS from 89% to 93% at 4 years, with improved disease-free survival and reduction in the rate of distant metastasis. The trial suggests that docetaxel CT may be an option to be discussed with selected men with high-risk prostate cancer.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Rosenthal SA, Hu C, Sartor O, et al. Effect of Chemotherapy With Docetaxel With Androgen Suppression and Radiotherapy for Localized High-Risk Prostate Cancer: The Randomized Phase III NRG Oncology RTOG 0521 Trial. J Clin Oncol. 2019. PMID: 30860948. doi:10.1200/JCO.18.02158

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。